ClinicalTrials.gg
RecruitingNCT06043518Updated Nov 5, 2026

CNS Changes Following Upper Limb Loss

An observational study in Amputation, Congenital and Upper Limb; Amelia, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Zurich · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to better understand the structural and functional changes that the central nervous system (CNS) undergoes following congenital upper limb loss. The focus is on the brain's sensory processing and how neuronal changes may relate to clinical measures. By doing so, the hope is to gain insight into the contribution of critical periods to the plasticity of the sensorimotor processing stream. Both macroscopic and microscopic changes of the brain will be examined in individuals with upper limb amelia and compared to healthy controls. fMRI will be combined with behavioural testing to understand which clinical and behavioural determinants drive somatosensory representations along the entire somatosensory processing stream. Using advanced imaging techniques, the aim is to investigate the contribution of brainstem reorganisation to plasticity observed at the cortical level and, by doing so, gain a better understanding of the mechanistic underpinnings of functional reorganisation. Overall, the hope is to provide the first mechanistic insight into whether early life experiences are crucial for the development of the relay nuclei in the central nervous system and how these changes relate to clinical measures such as adaptive behaviours or pain.

02

Conditions studied

  • Amputation, Congenital
  • Upper Limb; Amelia

Keywords

  • Plasticity
  • Congenital amputee
  • Upper limb amelia
  • Somatotopy
  • Functional MRI
  • Hand
  • Reorganisation
03

In context

Lead sponsor

University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with an upper-limb amputation and healthy subjects.

Eligibility criteria

Inclusion Criteria - Patients:

  • Age 18-75
  • Upper-limb congenital amputees with complete absence of a hand
  • Signed

Exclusion Criteria - Patients:

  • to magnetic resonance imaging
  • Neurological impairment of body function impairments not induced by spinal cord injury
  • > 40
  • Pregnancy
  • Claustrophobia

Inclusion Criteria - Healthy subjects:

  • Age 18-75
  • Signed Informed consent

Exclusion Criteria - Healthy subjects:

  • Contraindications to magnetic resonance imaging
  • Pregnancy
  • Neurological illness
  • Impairment of body function induced by a congenital upper-limb amputation
  • Claustrophobia
  • BMI > 40
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with congenital amputation

    Diagnostic Test: MRI

  • Healthy subjects

    Diagnostic Test: MRI

Interventions

  • Diagnostic testMRI

    Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function

  • Diagnostic testMRI

    Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.

06

What researchers measure

Primary outcomes

  1. Change of functional MRI (fMRI) parameter between 2 to 4 time points

    Change of brain activities is assessed between 2 to 4 time points using fMRI during resting-state or a specific task in patients with congenital amputations and compared to healthy controls

    Time frame: Up to 50 weeks

Secondary outcomes

  1. Conventional magnetic resonance imaging (MRI) parameter

    Structural characteristics in the brain and cervical spinal cord are assessed in patients with congenital upper-limb amputations using conventional MRI and compared to healthy controls

    Time frame: Up to 50 weeks

  2. Amputees: Motor Activity Log questionnaire

    Evaluation of residual limb and/or prosthesis usage as compared to other body parts via a questionnaire and behavioural assessments.

    Time frame: Up to 50 weeks

07

Study locations

1 of 1 sites recruiting
  • Balgrist Campus
    Zurich, Canton of Zurich 8008, Switzerland
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2023 (actual). Primary completion is estimated for Jun 2028, 59 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2027 → Jun 2028 and completion Jun 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Jul 5, 2023
Primary completionEst.
Jun 30, 2028was Jun 2027
CompletionEst.
Jun 30, 2028was Jun 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2027→Jun 30, 2028
Nov 5, 2026
Study completion
Jun 30, 2027→Jun 30, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jun 30, 2027→Jun 30, 2028
    Study completion Jun 30, 2027→Jun 30, 2028
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06043518
Collaborators
ETH Zurich
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 5, 2023
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Paige Howell, PhD
Contact
paige.howell@hest.ethz.ch
+41 44 632 32 94
Sanne Kikkert
Contact
sanne.kikkert@balgrist.ch
+41 44 632 32 94
Patrick Freund, Prof.
principal investigator · University of Zurich

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion